The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide

[1]  T. Bertsch,et al.  Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy , 2020, Translational vision science & technology.

[2]  W. Rasband,et al.  Angiogenesis Analyzer for ImageJ — A comparative morphometric analysis of “Endothelial Tube Formation Assay” and “Fibrin Bead Assay” , 2020, Scientific Reports.

[3]  Zhijian Wu,et al.  Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis , 2020, Laboratory Investigation.

[4]  Y. Macotela,et al.  Prolactin stimulates the vascularisation of the retina in newborn mice under hyperoxia conditions , 2020, Journal of neuroendocrinology.

[5]  Hugo Cruces-Solís,et al.  Sequence optimization and glycosylation of vasoinhibin: Pitfalls of recombinant production. , 2019, Protein expression and purification.

[6]  Anping Li,et al.  Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy , 2019, Journal of Hematology & Oncology.

[7]  N. Ferrara,et al.  VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.

[8]  Asghar Fallah,et al.  Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  R. Garduño-Juárez,et al.  Vasoinhibin comprises a three-helix bundle and its antiangiogenic domain is located within the first 79 residues , 2018, Scientific Reports.

[10]  Carlos Fernandez-Lozano,et al.  Prediction of high anti-angiogenic activity peptides in silico using a generalized linear model and feature selection , 2018, Scientific Reports.

[11]  T. Bertsch,et al.  Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema , 2018, Front. Endocrinol..

[12]  Sanguthevar Rajasekaran,et al.  Minimotif Miner 4: a million peptide minimotifs and counting , 2017, Nucleic Acids Res..

[13]  K. Sliwa,et al.  Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study , 2017, European heart journal.

[14]  Jolene L. Lau,et al.  Therapeutic peptides: Historical perspectives, current development trends, and future directions. , 2017, Bioorganic & medicinal chemistry.

[15]  Martin J. Stoermer,et al.  Orally Absorbed Cyclic Peptides. , 2017, Chemical reviews.

[16]  L. C. Zepeda-Romero,et al.  Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity , 2017, Pediatric Research.

[17]  E. Martinez-Hackert,et al.  Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. , 2016, Analytical biochemistry.

[18]  Gordon C Jayson,et al.  Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.

[19]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[20]  R. Ge,et al.  Novel endogenous angiogenesis inhibitors and their therapeutic potential , 2015, Acta Pharmacologica Sinica.

[21]  S. Thébault,et al.  Vasoinhibins regulate the inner and outer blood-retinal barrier and limit retinal oxidative stress , 2014, Front. Cell. Neurosci..

[22]  P. Carmeliet,et al.  PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin , 2014, Nature Medicine.

[23]  Li V. Yang,et al.  In vitro cell migration and invasion assays. , 2014, Journal of visualized experiments : JoVE.

[24]  M. Presta,et al.  Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR , 2013, Angiogenesis.

[25]  C. Clapp,et al.  Prolactin and blood vessels: a comparative endocrinology perspective. , 2012, General and comparative endocrinology.

[26]  Zhijian Wu,et al.  Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability. , 2011, Investigative ophthalmology & visual science.

[27]  Y. Macotela,et al.  Prolactin and vasoinhibins: Endogenous players in diabetic retinopathy , 2011, IUBMB life.

[28]  Aleksander S Popel,et al.  Anti-angiogenic peptides for cancer therapeutics. , 2011, Current pharmaceutical biotechnology.

[29]  Syamantak Majumder,et al.  Inhibitory activity of the peptides derived from buffalo prolactin on angiogenesis , 2011, Journal of Biosciences.

[30]  Jing Chen,et al.  The mouse retina as an angiogenesis model. , 2010, Investigative ophthalmology & visual science.

[31]  S. Thébault,et al.  Peptide hormone regulation of angiogenesis. , 2009, Physiological reviews.

[32]  Emmanouil D Karagiannis,et al.  A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells , 2008, Proceedings of the National Academy of Sciences.

[33]  D. Hanahan,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[34]  H. Hernández-Montiel,et al.  Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. , 2008, The Journal of clinical investigation.

[35]  Timothy J. Mitchison,et al.  A chemical method for fast and sensitive detection of DNA synthesis in vivo , 2008, Proceedings of the National Academy of Sciences.

[36]  J. Foidart,et al.  Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  Carmen G. Gonzalez,et al.  Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia , 2007, Laboratory Investigation.

[38]  K. Sliwa,et al.  A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy , 2007, Cell.

[39]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[40]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[41]  J. Aranda,et al.  Vasoinhibins: endogenous regulators of angiogenesis and vascular function , 2006, Trends in Endocrinology & Metabolism.

[42]  R. Brasseur,et al.  Prolactin/growth hormone–derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis , 2006, Proceedings of the National Academy of Sciences.

[43]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[44]  Kaare Teilum,et al.  Solution structure of human prolactin. , 2005, Journal of molecular biology.

[45]  R. Russell,et al.  Linear motifs: Evolutionary interaction switches , 2005, FEBS letters.

[46]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[47]  M. Hodsdon,et al.  The tertiary structure and backbone dynamics of human prolactin. , 2003, Journal of molecular biology.

[48]  D. Hawke,et al.  Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. , 2003, Protein expression and purification.

[49]  Jeri Kim,et al.  Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. , 2003, Cancer research.

[50]  J. Martial,et al.  Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. , 2001, Cancer research.

[51]  C. Ruhrberg,et al.  Endogenous inhibitors of angiogenesis. , 2001, Journal of cell science.

[52]  Y. Cao,et al.  Endogenous angiogenesis inhibitors and their therapeutic implications. , 2001, The international journal of biochemistry & cell biology.

[53]  J. Martial,et al.  Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Jia-jia Yang,et al.  Advances in toxicity risk analysis and effective treatments for targeted antiangiogenic drugs , 2019 .

[55]  R. Bicknell,et al.  Tube-Forming Assays. , 2016, Methods in molecular biology.

[56]  S. Thébault,et al.  Regulation of blood vessels by prolactin and vasoinhibins. , 2015, Advances in experimental medicine and biology.

[57]  M. Hüfner,et al.  OF THE PROLACTIN / VASOINHIBIN AXIS , 2015 .

[58]  Christine Unger,et al.  In vitro cell migration and invasion assays. , 2013, Mutation research.

[59]  Katherine M Malinda,et al.  In vivo matrigel migration and angiogenesis assay. , 2009, Methods in molecular biology.

[60]  Michel Vaubourdolle,et al.  A protocol for isolation and culture of human umbilical vein endothelial cells , 2007, Nature Protocols.

[61]  R. Kalluri,et al.  Cited Articles Citing Articles E-mail Alerts Endogenous Inhibitors of Angiogenesis , 2022 .